Compugen Analyst Price Targets

Wall Street analyst price targets and consensus rating for Compugen (CGEN).

Price Target Range — 5 Quarters

Analyst Consensus — 5 Analysts

5Buy

Consensus RatingBuy# Analysts5Avg. Consensus PT$5Upside to Avg. PT+112.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
May 21, 2026	Leerink Partners	—	PT Cut	Outperform	$13→$5
Apr 7, 2026	Lake Street	Chad Messer	Initiate	Buy	$6
Jan 7, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	Initiate	Buy	$4
May 21, 2024	Truist Securities	Asthika Goonewardene	PT Cut	Buy	$5→$4
Mar 8, 2024	Truist Securities	Asthika Goonewardene	PT Raise	Buy	$4→$5
Dec 19, 2023	Stifel	Stephen Willey	PT Raise	Buy	$3→$4

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Leerink Partners Maintains Outperform on Compugen, Lowers Price Target to $5

Leerink Partners maintains Compugen (NASDAQ:CGEN) with a Outperform and lowers the price target from $13 to $5.

Benzinga Newsdesk

PRO
Lake Street Initiates Coverage On Compugen with Buy Rating, Announces Price Target of $6

Lake Street analyst Chad Messer initiates coverage on Compugen (NASDAQ:CGEN) with a Buy rating and announces Price Target of $6.

Benzinga Newsdesk

This Applied Digital Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday

Avi Kapoor

PRO
HC Wainwright & Co. Initiates Coverage On Compugen with Buy Rating, Announces Price Target of $4

HC Wainwright & Co. analyst Swayampakula Ramakanth initiates coverage on Compugen (NASDAQ:CGEN) with a Buy rating and announces Price Target of $4.

Benzinga Newsdesk

Alterity Up on Interim Data From Advance MSA Study

Shares of Alterity Therapeutics (NASDAQ: ATHE) were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 for treating patients with multiple system atrophy, a rare neurodegenerative disease.

Zacks

Lexeo Down Despite Upbeat Rare Disease Gene Therapy Data

Shares of Lexeo Therapeutics (NASDAQ: LXEO) lost 26% on Monday after it reported positive interim data from two cohorts of the phase I/II SUNRISE-FA study evaluating LX2006, an investigational gene therapy for treating Friedreich ataxia (FA) cardiomyopathy.

Zacks

Compugen Ltd

Compugen Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Leerink Partners Maintains Outperform on Compugen, Lowers Price Target to $5

PRO
Lake Street Initiates Coverage On Compugen with Buy Rating, Announces Price Target of $6

This Applied Digital Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday

PRO
HC Wainwright & Co. Initiates Coverage On Compugen with Buy Rating, Announces Price Target of $4

Alterity Up on Interim Data From Advance MSA Study

Lexeo Down Despite Upbeat Rare Disease Gene Therapy Data

People Also Watch

People Also Watch

Compugen Ltd

Compugen Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROLeerink Partners Maintains Outperform on Compugen, Lowers Price Target to $5

PROLake Street Initiates Coverage On Compugen with Buy Rating, Announces Price Target of $6

This Applied Digital Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday

PROHC Wainwright & Co. Initiates Coverage On Compugen with Buy Rating, Announces Price Target of $4

Alterity Up on Interim Data From Advance MSA Study

Lexeo Down Despite Upbeat Rare Disease Gene Therapy Data

People Also Watch

People Also Watch

PRO
Leerink Partners Maintains Outperform on Compugen, Lowers Price Target to $5

PRO
Lake Street Initiates Coverage On Compugen with Buy Rating, Announces Price Target of $6

PRO
HC Wainwright & Co. Initiates Coverage On Compugen with Buy Rating, Announces Price Target of $4